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Background Existing preclinical murine models often fail to predict effects of anti-cancer 
drugs. In order to minimize interspecies-differences between murine hosts and human bone 
tumors of in vivo xenograft platforms, we tissue-engineered a novel orthotopic humanized 
bone model. 
Methods Orthotopic humanized tissue engineered bone constructs (ohTEBC) were fabricated 
by 3D printing of medical-grade polycaprolactone scaffolds, which were seeded with human 
osteoblasts and embedded within polyethylene glycol-based hydrogels containing human 
umbilical vein endothelial cells (HUVECs). Constructs were then implanted at the femur of 
NODscid and NSG mice. NSG mice were then bone marrow transplanted with human CD34+ 
cells. Human osteosarcoma (OS) growth was induced within the ohTEBCs by direct injection 
of Luc-SAOS-2 cells. Tissues were harvested for bone matrix and marrow morphology 
analysis as well as tumor biology investigations. Tumor marker expression was analyzed in 
the humanized OS and correlated with the expression in 68 OS patients utilizing tissue micro 
arrays (TMA). 
Results After harvesting the femurs micro computed tomography and immunohistochemical 
staining showed an organ, which had all features of human bone. Around the original mouse 
femur new bone trabeculae have formed surrounded by a bone cortex. Staining for human 
specific (hs) collagen type-I (hs Col-I) showed human extracellular bone matrix production. 
The presence of nuclei staining positive for human nuclear mitotic apparatus protein 1 (hs 
NuMa) proved the osteocytes residing within the bone matrix were of human origin. Flow 
cytometry verified the presence of human hematopoietic cells. After injection of Luc-SAOS-2 
cells a primary tumor and lung metastasis developed. After euthanization histological analysis 
showed pathognomic features of osteoblastic OS. Furthermore, the tumor utilized the 
previously implanted HUVECS for angiogenesis. Tumor marker expression was similar to 
human patients. Moreover, the recently discovered musculoskeletal gene C12orf29 was 
expressed in the most common subtypes of OS patient samples. 
Conclusion 
OhTEBCs represent a suitable orthotopic microenvironment for humanized OS growth and 
offers a new translational direction, as the femur is the most common location of OS. The 
newly developed and validated preclinical model allows controlled and predictive marker 
studies of primary bone tumors and other bone malignancies.  
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Main Text 
Introduction 
Surgical techniques for reconstruction of the affected limb have evolved and improved quality 
of life of osteosarcoma (OS) patients significantly and neoadjuvant chemotherapy increased 
survival of these patients (6,7). Yet, therapeutic regimens have reached an efficacy plateau at 
a 60-70 % survival rate over the last two decades. Most patients suffer from the consequences 
of metastatic disease that is treated via systemic administration of anti-tumor agents [1, 2]. So 
far, conventional preclinical syngeneic and xenogeneic OS models failed to enhance the 
translation of novel therapeutic agents into clinical practice. Species-specific incompatibilities 
between human and murine organisms have become a concern when tumor development and 
responsiveness to new therapeutics are investigated in xenograft models [3]. Differences in 
nucleic- and amino-acid sequences of regulatory genes and proteins - resulting in altered 
crosstalk within inter- and intracellular signalling networks - are the main reason for 
unsuccessful translation of experimental research data acquired from murine models [4].  
The role of not only implanting human cells but also humanizing the stroma that encompasses 
the tumor has become increasingly important in modern cancer research and in the 
development of more clinical relevant mice models.[3, 5-8]. Recently, humanized in vivo 
models have been developed in order to investigate the biology and homing of human 
osteotropic tumors like breast and prostate cancer within a human bone microenvironment [7, 
9, 10]. Up-to date transplantation techniques utilize subcutaneous and therefore ectopic 
engraftment of humanized bone tissue [11-14]. However, a humanized orthotopic model 
would have several advantages, as the local tissue microenvironment plays an important role 
on the function of engrafted tissues[15].  
To the best of our knowledge, we herein for the first time describe a novel surgical approach 
combined with a clinically-established bone tissue engineering technology to generate a 
scaffold-based humanized bone organ within the continuity of the murine skeleton and 
particularly within the anatomic context of the mouse femur. This makes it possible to 
generate human extracellular bone matrix components as well as human mesenchymal and 
hematopoietic cellular elements at the typical anatomic site of human OS growth. We also 
demonstrate that human OS established within this humanized microenvironment utilizes the 
co-implanted human endothelial cells for tumor angiogenesis. Moreover, we show that the 
recently discovered gene C12orf29 [16] is being expressed in both our humanized OS model 
and in OS patients and may represent a potential new biomarker. The orthotopic humanized 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
tissue-engineered bone construct (ohTEBC) technology platform offers new translational 
research directions, as the femur is not only the most common site of OS, but also of many 
other primary and secondary bone tumors [2].  
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Materials and Methods 
Animal housing and handling 
All animal studies were performed according to the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes and approved by the Animal Ethics Committee of 
the University of Queensland (approval number QUT/IHBI/376/14/ARC). NOD-scid mice 
(NOD.CB17-PrkdcSCID/Arc) and NOD-scid γ (NSG; NOD.Cg-PrkdcSCIDIl2rgtm1Wjl/SzJ) mice 
were purchased from the Animal Resources Centre (Canning Vale, WA, Australia). Either 4-6 
weeks old female immuno-compromised non-obese diabetic/severe combined 
immunodeficient (NOD-scid) or NSG mice were used as recipients. Animals were housed at 
the Translational Research Institute (Biological Resource Centre, Brisbane, Australia) and 
maintained under pathogen-free conditions. Animals had free access to sterilized food and 
water ad libitum and at least a one-week acclimatization phase before experiments 
commenced. 
Engineering of ohTEBCs 
OhTEBCs were generated according to a standardized institutional protocol [9]. Figure 
1 depicts the setup of the engineered constructs. Melt electrospinning writing (MEW) was 
applied to fabricate tubular medical-grade PCL (mPCL, molecular weight 50kD) scaffolds as 
described previously [9]. Scaffolds measured 2 mm in diameter and 5 mm in length. The 
mPCL surface was coated with calcium phosphate (CaP) to enhance adhesion and 
differentiation of human mesenchymal progenitor cells (hMPC) [17], which were isolated 
from human bone acquired from patients undergoing hip arthroplasty as approved by the 
ethics committees of the Queensland University of Technology and the Prince Charles 
Hospital, Brisbane (approval number 0600000232) as previously described [18]. Samples 
were collected under informed consent. Scaffolds were sterilized via exposure and 
evaporation of 70% ethanol in a biosafety cabinet, followed by transfer into a sterile petri dish 
and exposure to UV light for 30 min. Then, scaffolds were seeded with 7.5x105 hMPCs and 
cultured under standard conditions for 2 weeks at 37° C, 5% CO2 and 21% O2 in alpha 
minimum essential medium (α-MEM) supplemented with 10% foetal bovine serum (FBS), 
100 IU/ml penicillin and 100 µg/ml streptomycin (all from Life Technologies, Australia). 
Medium was changed every 3-4 days. After a 2-week proliferation phase, hMPCs were 
osteogenically stimulated by adding 0.1 µM dexamethasone, 150 µM phosphoascorbic acid 
and 10 mM β-glycerophosphate (all from Sigma-Aldrich, Australia) to the culture medium for 
additional 5 weeks and medium changed every 3-4 days. Cell viability and cell architectural 
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analysis has been performed prior to implantation according to our standardized 
institutional protocols as described before [9, 17, 19-24]. 
Pre-vascularized construct preparation 
Human umbilical vein endothelial cells (HUVEC, Stemcell Technologies, Canada) were 
transduced with GFP-lentivirus and sorted for green fluorescent protein positive (GFP+) cells 
using a FACS Aria III cell sorter (BD Biosciences, USA). Seven days prior to implantation, 
the hMPC-seeded and osteogenically differentiated scaffolds were combined with 4.8x105 
HUVEC+GFPs suspended in 48 µL star-PEG heparin hydrogels (stiffness 600 Pa) at a cross-
linking degree of 2.5 and with molar ratio of linear RGD tripeptide (Arg-Gly-Asp) of 2:1 
according to a standardized institutional protocol [19, 25]. Hydrogels were loaded with 5 
µg/mL vascular endothelial growth factor (VEGF; Prospec Bioscience, Israel) to support 
angiogenic sprouting and cultured in endothelial growth medium-2 (EGM-2; Promocell, 
Germany). Additional samples were set up using HUVEC+GFPs for performing a cell 
viability assay. Cell viability was evaluated at day 7 using fluorescein diacetate (FDA, Life 
Technologies) and propidium iodide (PI, Life Technologies). Specimen were washed in PBS 
and incubated with FDA 10 µg/ml FDA and 5 µg/ml PI in the dark at 37° C for 5 minutes. 
Samples were then washed with PBS and visualized directly using a Leica SP5 confocal 
microscope (Leica, Australia, Supp. Fig.1). Constructs with HUVEC+GFPs were fixed at day 
7 with 4% paraformaldehyde to assess the formation of capillary-like structures upon 
visualization of the GFP signal produced by the cells with a Nikon A1R confocal microscope. 
HUVEC viability and vascularization architecture analysis has been performed prior to 
implantation as described before [19]. 
 
Implantation of ohTEBCs 
Lateral skin incisions were performed at the right upper hind leg (Figure1C iv). The femur 
was exposed after blunt muscle dissection. Two 0.5 mm cortical windows were created at the 
anterior femur utilizing a 27-gauge needle (Braun, Australia) drilled into the bone cortex to 
facilitate the exchange and migration of the implanted human cells with the mouse bone 
marrow. The ohTEBC was wrapped around the femur following the addition of 10 µL 
rhBMP-7 (concentration 1 µg/µL, Olympus Biotech Corporation, USA) embedded in 20 µL 
of fibrin glue (10 µL thrombin and 10 µL fibrinogen; TISSEEL FibrinSealant, Baxter 
Healthcare International, USA). In an additional cohort of mice, 2.25 × 105 human bone 
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marrow-derived MSCs (hBM-MSC) suspended in 10 µL PBS were mixed with the fibrin glue 
and rhBMP-7 solution which was placed between the scaffold and the murine bone. After 
polymerization of the fibrin glue, the divided muscles were readapted with resorbable 4-0 
vicryl sutures (Ethicon, USA) and skin closure followed with metal clips (9 mm Autoclips, 
Kent Scientific Corp., USA). OhTEBCs were allowed to form a bone organ for 6 weeks in 
vivo. Thereafter, mice with and without hBM-MSCs (n = 5 each)   
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Figure 1: (A) Schematic overview and cross-sectional view (B) of orthotopic humanized 
tissue engineered bone constructs (ohTEBC) located around the murine femur. (C) Tissue 
engineering of ohTEBCs by generating tubular scaffolds via melt electrospinning (C i). 
Human mesenchymal progenitor cells (hMPCs) are isolated from human bone harvested 
during hip arthroplasty (C ii). Scaffolds are then seeded with hMPCs and osteogenically 
differentiated (C iii). After lateral skin incision and exposure of the femoral diaphysis, 
ohTEBCs are placed around the femur (C iv).   
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Figure 2: Experimental time line for humanized OS investigations. OhTEBCs were 
implanted at the femur of NOD-scid and NSG mice. Only NSG mice were transplanted with 
human CD34+ HSCs after 5 weeks. Luc-SAOS-2 cells were injected into ohTEBCs 20 weeks 
after ohTEBC-implantation in NSG mice and 6 weeks after ohTEBC-implantation in NOD-
scid mice. Regarding NOD-scid mice, 10 animals were not injected with tumor cells but 
sacrificed for bone property analysis at this time point. In 5 of these mice hBM-MSCs were 
added to the constructs at the time point of ohTEBC-implantation. 
 
 
were sacrificed for further analysis. One part of the remaining mice was assigned for the OS 
model where human OS cells were injected to investigate the biology of human primary bone 
tumors developing within the humanized bone microenvironment. An additional cohort of 
NSG mice were also transplanted with human CD34+ cells to establish a humanized 
hematopoietic and immune system. OhTEBCs were analyzed for their level of humanization.  
SAOS-2 cell culture 
Human osteosarcoma SAOS-2 cells were purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia, Lot# 10C019) originally derived from a 11 year-old girl as described by Fogh et al. 
in 1977 [26]. Luciferase-expressing SAOS-2 cells (Luc-SAOS-2) were generated using a 
lentiviral gene expression system according to the manufacturer’s instructions (Life 
Technologies). Cells were grown in McCoy’s 5A modified medium (Flow Laboratories, 
USA) containing 10% FBS, 100 IU/mL penicillin and 100 µg/mL streptomycin at 37° C, 5% 
CO2 and 21% O2.  
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Development of a humanized OS platform 
To develop a humanized OS platform, 5x105 Luc-SAOS-2 cells were suspended in 50 µL 
PBS. Cells were placed into the ohTEBCs of NOD-scid and NSG mice via direct 
percutaneous injection after hair removal and disinfection under general isoflurane 
anesthesia. Directly after Luc-SAOS-2 cell injection, BLI was performed in order to 
confirm orthotopic placement of the cells and weekly to monitor tumor growth and to 
detect metastasis in vivo over 8 weeks in the NOD-scid group and 7 weeks in the NSG group. 
Animals were sacrificed by CO2 asphyxiation and the humanized femurs containing the 
ohTEBC and OS, the contralateral femurs and the murine lungs were excised followed by ex 
vivo bioluminescence imaging (BLI; IVIS Spectrum 200, Perkin Elmer, USA). After fixation 
of the specimen in 4% paraformaldehyde for 24 h at 4° C, specimens were transferred to 70% 
ethanol and stored at 4° C for further analyses. Additional specimens were stored in RNA 
LaterTM (QIAGEN, USA) at -80° C. 
Bioluminescence Imaging 
BLI was used to monitor tumor spread. Therefore, 100 µL (7.5 mg/mL) luciferin 
(PerkinElmer, USA) was injected intraperitoneally and mice were imaged after 15 min under 
general isoflurane anesthesia. During the same experimental session, X-ray analysis of 
ohTEBCs was performed using an ultrafocus 100 planar X-ray (Faxitron, USA). To determine 
tumor and metastatic spread ex vivo, luciferin was injected 15 minutes prior to euthanization 
of animals via CO2 asphyxiation. The femur carrying ohTEBCs and OS as well as the 
unmodified contralateral femurs and the murine lungs were excised and BLI images generated 
15 min after luciferin injection. Living Image Software  4.5.2 (Perkin Elmer) was used for 
analysis. A threshold of 10% around each bioluminescent source was set to determine the 
amount of photons emitted within a given time [10]. Signals higher than 150 counts were 
considered positive.  
Micro-computed tomography (µCT) 
Ex vivo µCT scanning (µCT 40, Scanco Medical AG, Switzerland) of ohTEBCs was 
performed at a voxel size of 16 µm. Samples were imaged in 70% ethanol in a 25 mm 
diameter tube. The evaluation threshold was set at 150 with a filter width of 0.8 and a filter 
support of 1. A standard curve was acquired after scanning hydroxyapatite phantoms with a 
known mineral density to correlate the X-ray attenuation to the sample density. The 
guidelines described by Bouxsein et al. were used to calculate bone volume (BV, mm3), total 
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volume (TV, mm3) and bone volume fraction (BV/TV %) [27]. To asses these values and to 
compare results between groups, whole femurs carrying ohTEBCs were scanned. To calculate 
differences between orthotopic bone and ectopic bone and to estimate the original femur 
parameters, the contralateral femur was scanned. 
Magnetic resonance imaging (MRI) 
A MRI scanner (BRUKER DRX Micro Imaging System, Rheinstetten, Germany) operating at 
300MHz per proton and equipped with a micro 2.5 gradient system was used to depict 
orthotopic bone and OS morphology. Specimen were placed into a 15 mm tube containing 
70% ethanol. A preliminary image scout was performed to adjust sample positioning and 
scanner settings. ParaVision Software (Bruker BioSpin) was used for picture generation and 
analysis. The following acquisition parameters were applied: in plane matrix size 256 x 256; 
effective spectral bandwidth 100 MHz; echo time 7.0 ms; repetition time 1,000 ms; number of 
averages 16; total scan time 1h 8m 16s; field of view 18.0 mm; slice thickness 0.8 mm. 
Standard multi-spin-multi-echo (MSME) pulse sequence was used for relaxation 
measurements.  
Histology and Immunohistochemistry (IHC) 
Fixed samples were decalcified with 10% ethylenediaminetetraacetic acid (EDTA; pH 7.4) at 
37 ˚C for 4-6 days utilizing a Rapid Decalcifier (Milestone, KOS Microwave Histostation, 
ABACUS ALS, Meadowbrook, Australia). Paraffin sections with a thickness of 5 µm were 
generated following a standard protocol to perform haematoxylin and eosin (H&E) staining 
[28]. After dewaxing and rehydration, sections were incubated with proteinase K (Dako, New 
South Wales, North Sydney) at room temperature (RT) or placed into antigen retrieval 
solutions (see Supp. Table 1). To quench endogenous peroxidase activity, specimens were 
incubated with 3% hydrogen peroxide (Sigma-Aldrich) for 5 min. After quenching, the 
samples were incubated with 2% bovine serum albumin (BSA, Sigma-Aldrich) for 30 min at 
RT to block, followed by primary antibodies in 2% BSA for 1 h at RT and 30 min with 
EnVision+ Dual Link System-HRP rabbit/mouse (Dako). Diaminobenzidine chromogen 
(DAB, Dako) was used for colour development. Developing times were kept identical to 
compare between groups. Counterstaining was performed with Mayer’s haematoxylin 
(Sigma-Aldrich). Human tissue, murine bone, lung and kidney sections were used as positive 
and negative controls, respectively. Initial analysis of the samples was performed using a 
Nikon Eclipse E200MVR microscope (Nikon, Japan). For detailed and software based 
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analysis, sections were scanned with a Leica SCN 400 slide scanner (Leica Microsystems, 
Germany) at a 40x magnification. 
For immunofluorescence staining, antigen retrieval was performed with sodium citrate buffer 
(ph6.0) for 5 min at 95˚C in a decloaking chamber. Human-specific CD34 (hsCD34; 1:300 
dilution; Abcam, Australia) and anti-GFP antibodies (1:100 dilution; Life Technologies) were 
used in a 2% BSA solution. Sections were incubated overnight at RT. After washing, sections 
were incubated with Alexa Fluor A568 (Life Technologies) and Alexa Fluor 488 (Life 
Technologies) for 30 min. Samples were washed again and counterstained with 4’,6-
diamidino-2-phenylindole dihydrochloride (DAPI; 1:1000 dilution; Sigma-Aldrich) and 
mounted with ProLong® Gold antifade reagent (Life Technologies). Then, sections were 
imaged with a Zeiss Axio Imager.M2 fluorescence microscope (Zeiss, Germany). 
Histomorphology 
Histomorphological analysis was performed with ImageScope (Version 12.2.2.5015, Aperio 
Technologies). To calculate the percentage of blood-containing marrow, randomly assigned 
H&E sections of every animal per group were taken and the area [mm3] of the BM cavity of 
each section was determined. Then, the area containing hematopoietic cells was measured and 
the ratio between blood-containing marrow and the entire bone cavity was calculated. Results 
were expressed as mean percentage per group ± standard error of the mean (± SEM). For cell 
counts, the ImmonuRatio Software (Institute of Biomedical Technology, University of 
Tampere, Finland) was utilized. The region of interest (ROI) was defined and thresholds for 
brown and blue colours were adjusted in a preliminary analysis (-30 to 0), and correctness 
was verified via visual analysis by an independent person. To determine differences between 
groups, analysis parameters were unchanged during analysis to assure standardized evaluation 
of the images. Results were expressed as mean percentage of positive cells ± SEM. 
Tartrate resistant acid phosphatase (TRAP) staining 
Deparaffinised and rehydrated sections were washed in deionized water (DI) and then 
incubated for 20 min at RT in 0.2 M acetate buffer containing 0.2 M sodium acetate (Sigma-
Aldrich) and 50 mM sodium L-tartrate dehydrate (Sigma-Aldrich). Naphtol AS-MX 
phosphate disodium salt (Sigma-Aldrich) and fast red TR salt 1,5-napthalenedisulfonate salt 
(Sigma-Aldrich) were added to the same acetate buffer to a final concentration of 0.5 mg/ml 
and 1.1 mg/ml respectively. After incubation at 37°C for 1.5 h, samples were rinsed in DI 
water and counterstained with Mayer’s haematoxylin and scanned as per IHC procedure. 
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Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis 
RNA was isolated and purified using the Direct-zol™ RNA miniprep Kit (Zymo Research, 
CA, USA) following manufacturer’s instructions. Briefly, one volume ethanol (95-100%) was 
added directly to the samples homogenised in TRIzol® reagent and vortexed. Mixtures were 
then loaded into a Zymo-Spin™ IIC column and centrifuged at ~12,000g. Spin columns were 
treated with DNase at RT. Columns were washed and RNA eluted using 30-50 µL RNase-free 
MilliQ water and stored at -80 °C until further use. RNA quality was determined with a 
Nanodrop® ND-1000 spectrophotometer (Thermo Scientific, USA) and samples with 
A260nm/230nm = 2.00-2.2 were synthesized into cDNA using a Superscript™ III first-strand 
synthesis supermix (Life Technologies) following manufacturer’s instructions. QRT-PCR was 
performed with SYBR® green chemistry using an ABI Prism® 7500 sequence detection 
system (Applied Biosystems, Australia). Gene-specific primers are listed in Supplemental 
Table 2. The cycle threshold (Ct) value for each gene was determined and normalized to 18S 
rRNA levels and compared to the control (∆∆Ct). Relative gene expression between groups 
was calculated using the 2-∆∆Ct method. 
Flow cytometry 
Murine femora, spleens and ohTEBCs were harvested immediately after euthanasia by 
removing all remaining soft tissue with scissors. The bones were crushed with mortar and 
pestle in ice-cold PBS supplemented with 2% FCS and filtered through a 40 µm cell strainer 
(Corning, Falcon, USA). Murine BM was harvested by flushing the femora with PBS 
supplemented with 2% FCS and then filtered through a 40 µm cell strainer. After centrifuging 
at 400 g for 5 min, both cell suspensions were re-suspend in aliquots of 1x106 BM per 100 µL 
PBS. PBS containing live/dead aqua (1:1,000; Life Technologies) were incubated on ice for 
15 min. Anti-human and anti-mouse FcγIII/II receptor (Cd16/Cd32) blocking antibodies 
(1:100; Biolegend) were incubated for 15 min on ice. Cells were then stained for 15 min on 
ice by adding the following antibody mix: muCD45-PB, huCD45-PE-Cy7, huCD34-PE 
(Biolegend, USA). Anti-mouse antibodies were diluted 1:100 and the anti-human antibodies 
1:200. Note that both anti-human CD45 and anti-mouse CD45 fluorescent antibodies were 
used for staining to calculate frequency of each individual human or murine cell type relative 
to total number of leukocytes (human plus murine) contained in the BM. Cells were then 
washed with MACS buffer (PBS, 2mM EDTA, 0.5% BSA), centrifuged at 400 g for 5 min, 
re-suspended in MACS buffer and acquired with the BD LSRFortessa X-20 cytometer (BD 
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Biosciences, USA). Fluorescence-minus-one controls (FMOs) for all antibodies was used for 
setting the threshold of positivity.  
 
Tissue microarray (TMA) analysis 
TMAs were generated, processed and analyzed at the Departments of Pathology and 
Orthopedic Surgery of the Klinikum rechts der Isar (Technical University of Munich, 
Germany) and purchased from Biomax US (OS840b; USA) as approved by the human ethics 
committee of the Technical University of Munich (approval number 440/15s). The 
retrospective cohort from the Technical University of Munich consisted of patients without 
neoadjuvant chemotherapy and patients who underwent surgical resection of high-grade 
central OS prior to chemotherapy between 2008 and 2015 at the Klinikum rechts der Isar 
(Table 1). Specimen from 7 cases were available of both prior to and after chemotherapy. 
H&E-stained sections including the additional commercially available 40 duplicate cases 
from Biomax were reviewed by an experienced pathologist (M.B.) and orthopedic surgeon 
(P.P.). Grading and staging were undertaken according to the current World Health 
Organization Classification of Tumors of   
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Sex     Subtype*     Tumour site*     UICC Stage*   
Male 41 
 
Osteoblastic 41 
 
Femur 37 
 
IA 2 
Female 27 
 
Mixed osteo-
/chondroblastic 11 
 
Tibia 7 
 
IB 3 
Total 70 
 
Chondroblastic 8 
 
Humerus 8 
 
IIA 9 
  
  
Fibroblastic 3 
 
Fibula 2 
 
IIB 26 
 
  
 
Small cell OS 1 
 
Ilium 1 
  
  
 
 
 
Giant cell OS 1 
 
Sacrum 1 
  
  
 
 
    
Rib 3 
  
  
Grading*   
  
Scapula 2 
  
  
I 0 
    
Lung metastasis 1 
  
  
II 1     Jaw/temporal 5  
III 27 
 
 
  
  * where data available 
 
Table 1: Patients’ characteristics.  
 
Head and Neck (2004) and the AJCC tumor, node, metastasis (TNM) classification. 
Morphological grades of post-chemotherapy regression were assessed according to Salzer-
Kuntschik et al. guidelines [29]. Clinicopathological data including age, gender, localization 
of primary tumor was provided by P.P.  
TMA construction. Formalin-fixed paraffin-embedded tumor samples from preoperative 
biopsies, primary and postoperative resection specimen were assembled into TMAs using a 
Tissue Microarrayer (Beecher Instruments, USA) with a core size of 0.6 mm. A minimum of 
3 cores were taken from the tumors in areas previously marked by a pathologist (B.S.). 
Biomax TMAs were processed as described by the company, with duplicates per patient.  
TMA analysis. Between 2 and 4 cores per patient were available for analysis. Cores which 
showed less than one third of total core size were not evaluated [30]. One image of the upper 
and lower region of each core were obtained and analyzed for the percentage of positively 
stained cells via Image scope by two independent examiners and experienced orthopedic 
surgeons (F.W. and C.L.) as described above. The mean percentage ± SEM of each patient 
was calculated. 
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Statistical analysis 
IBM SPSS Statistics (version 23.0) was used for descriptive statistics. SigmaPlot (Systat 
Software Inc. CA, USA) was used for further statistical analysis and graph acquisition. Data 
was tested with the Shapiro-Wilk normality test and Levene-test to verify normal distribution 
and then further analyzed either with the student t-test or Mann-Whitney U test to evaluate 
differences between the groups. The level of significance was set at p < 0.05. Results were 
expressed are expressed as the mean ± SEM. Linear regression analysis was performed for 
TMAs to evaluate significant correlation between expression patterns and R2 calculated [31]. 
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Results 
Convergence of minimal invasive surgery and regenerative medicine concepts to 
engineer a humanized organ bone at an orthotopic site 
We sought to tissue-engineer humanized bone at the orthotopic femoral site in order to 
partially replace the murine counterpart (Fig. 1&2). For this purpose, we 3D printed tubular 
mPCL scaffolds (5 mm long, 2 mm in diameter) utilizing MEW [9, 32, 33]. Scaffolds were 
coated with CaP and seeded with hMPCs, derived from patients undergoing hip arthroplasty. 
One week prior to surgical implantation, star-shaped polyethylene glycol-based (starPEG)-
heparin hydrogel containing GFP-labelled HUVECs were prepared to generate pre-capillary 
networks and humanize the vascular bone marrow (BM) niche [19, 34]. Our group recently 
showed that the addition of rhBMP-7 is not only instrumental to induce human bone matrix 
formation within murine hosts but is also essential for the development of a BM niche and the 
migration of hematopoietic cells into the organ bone [9, 10, 21, 35]. Utilizing conventional X-
Ray analysis, we found in vivo bone formation around the murine femur as early as 2 weeks 
post-implantation (Fig. 3A). After 6 weeks, NOD-scid mice (n = 5) were sacrificed and 
femurs with the newly-formed bone were harvested. Micro-computed tomographic (µCT) 
analysis showed radiopaque-appearing matrix formation with a BM cavity in between 
trabeculae, both surrounded by an osseous cortex (Fig. 3B). H&E staining demonstrated all 
morphological features found in a viable organ bone including osteocytes embedded in 
extracellular matrix (ECM) and hematopoietic BM including well expanded sinusoids filled 
with murine erythrocytes and all subsets of leukocytes (Fig. 3C). IHC staining for human-
specific collagen type-I (hsCol-I) proved that not only the implanted scaffolds consisted of 
human collagen-I but also that areas of the newly formed bone in the periphery were of 
human origin (Fig. 3D).  
Collagen type-II (Col-II) positive areas were found at the interjection of the murine femur and 
ohTEBCs, indicative of endochondral humanized bone formation at the surface of the mouse 
femur (Fig. 3E). Although Scotti et al. proved that human MSCs – seeded on a collagen-based 
scaffold – contributed to the enchondral bone formation by a “developmental engineering” 
process in which human MSCs were activated towards an enchondral ossification route, we 
cannot prove if the enchondral ossification is solely human in our experiment, as we did not 
utilize a human-specific Col-II antibody [36]. Additional staining for human-specific nuclear 
mitotic apparatus protein 1 (hsNuMa) showed that viable human cells were residing within  
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Figure 3: Orthotopic humanized tissue engineered constructs (ohTEBCs) contained human 
cellular and extracellular matrix (ECM) components after 6 weeks of bone remodelling in 
NOD-scid mice. (A) X-ray showed bone formation at the femur 2 weeks post-implantation of 
ohTEBCs. (B) After 6 weeks, µCT showed the murine femur (MF) in the longitudinal plane 
surrounded by new bone with a bone marrow cavity and an outer cortex (Cx). (C) Overall 
histomorphology in the cross-sectional view via H&E staining indicates the initially generated 
cortical window for cellular communication between the bone marrow compartments (arrow). 
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The new bone enclosed blood-containing marrow (BM) and fat marrow (FM). MMC = mouse 
medullary canal. (D) Positive staining for human specific collagen-I (hsCol-I, black arrow) 
confirmed the presence of human ECM in regions of the newly formed bone. Next to it, areas 
of murine bone were found (white arrow). (E) Col-II (white arrow heads) was found at the 
junction between the MF and new bone (NB), illustrating enchondral bone formation. (F) 
Human cells were found in the new bone as denoted by positive human-specific nuclear 
mitotic apparatus protein 1 (hsNuMa; white arrow heads) staining. (G) Human specific 
CD146+ (hsCD146) cells were detected within ohTEBCs, indicating the presence of human 
mesenchymal stem cells (white arrow heads). Black arrow heads depict areas where mPCL 
was dissolved during histology tissue preparation. 
 
the new bone (Fig. 3F). The abundance of osteoclasts, depicted by tartrate resistant acid 
phosphatase (TRAP) staining, demonstrated the functionality of the bone matrix and a 
physiological bone remodelling process (Supp. Fig. 2). Staining for hsCD146 revealed the 
presence of human MSCs (Fig. 3G), particularly within the perivascular BM niche [37]. We 
confirmed that the implanted hBM-MSCs (CD146+ cells) were still viable within the 
ohTEBCs (Fig. 3G), hence, these cells contribute to the formation of the BM niche. 
 
Addition of human BM-MSCs alters the properties of the BM compartment and 
increases the level of humanization 
As demonstrated previously, hBM-MSCs not only support the formation of mineralized 
matrix but also of the perivascular niche within the BM, promoting the recruitment of 
hematopoietic stem cells (HSCs) [12, 38, 39]. Therefore, we added undifferentiated hBM-
MSCs to the fibrin matrix when implanting the scaffolds in an additional group of NOD-scid 
mice (n = 5). According to µCT analysis, there were no significant differences in total 
ohTEBC volume (TV) as well as bone volume (BV; Fig. 4A) between both groups after 6 
weeks. However, we found a significantly lower BV/TV ratio in ohTEBCs when hBM-MSCs 
were added, indicating a larger BM cavity in this group (Fig. 4B). We used bone 
histomorphometric analysis and compared the area of blood cell-containing BM and adipose 
tissue-containing marrow, demonstrating a significantly higher percentage of blood cell-
containing marrow in ohTEBCs with hBM-MSCs (Fig. 4C). As the “level of humanization” 
is defined as the percentage of human tissue components within the engineered organ, 
additional analysis proved that these cells contributed to a higher level of bone matrix 
humanization, when calculating the amount of hsNuMA positive cells per scaffold area within 
the ohTEBCs (Fig. 4D). In order to evaluate differences in bone formation between an ectopic 
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Figure 4: Addition of human bone marrow-derived mesenchymal stem cells (hBM-MSC) to 
the orthotopic humanized tissue engineered constructs (ohTEBCs) increased humanization 
and homing of hematopoietic cells. (A) Bone volume (BV) was not different when adding 
hBM-MSCs to ohTEBCs during implantation. (B) Bone/total volume (TV) was significantly 
lower in the hBM-MSC group. (C) The percentage of blood cell-containing marrow was 
significantly higher in the hBM-MSC group compared to controls. (D) The proportion of 
human cells within the implanted scaffolds was higher in the hBM-MSC group as shown by a 
higher percentage of human-specific nuclear mitotic apparatus protein 1 (hsNuMa) positive 
cells. (E) BV was significantly higher in the orthotopic group compared to the ectopic group 
after subtracting BV and TV of the contralateral femur in the orthotopic group. Graphs depict 
boxplots showing bottom and top of box = 25th and 75th percentiles, thick line inside box = 
mean, thin line inside box = median, bar = maximum and minimum of data, black dots = 
outliers. * indicates significant differences between groups. n = 5 per group. 
 
and an orthotopic site, we also implanted hTEBCs subcutaneously in NOD-scid mice (n = 5) 
and performed µCT analysis after 6 weeks. We found a significantly higher amount of BV in 
the orthotopic group than in the ectopic group (Fig. 4E). Of note, we subtracted the BV 
parameters of the contralateral untreated femur from the orthotopic bone parameters to avoid 
false high BV values. This results suggest that the murine peri-femoral environment is more 
conductive to the formation of bone matrix and BM components within the tissue engineering 
construct compared to the ectopic subcutaneous implantation site. This is possibly due to the 
already present viable femoral bone and musculature enabling an early vascularization in 
comparison to ectopic tissue components in the subcutaneous microenvironment. 
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 Transplantation of human CD34+ cells generated a humanized BM compartment 
In order to humanize the BM hematopoietic compartment of the humanized orthotopic bone, 
we implanted ohTEBCs into NSG mice (n = 11) as these have been described to engraft 
human hematopoietic tissue more efficiently compared to NOD-scid mice (Fig. 5A)[40-42]. 
Five weeks post-implantation, mice were irradiated with 2.0 Gy for myeloablation and then 
transplanted with 1.5x105 human CD34+ cells (Lonza, USA) via intravenous injection. Ten 
additional mice without prior ohTEBC implantation were also transplanted and served as 
control group. At 10, 12, 14 and 16 weeks after ohTEBC implantation, peripheral blood (PB) 
was harvested for flow cytometry analysis to investigate circulating human HSCs and 
multilineage reconstitution (Fig. 5B-E). We detected not only a high percentage of total 
human hematopoietic (hCD45+) and stem (hCD34+) cells, but also found the expected 
peripheral reconstitution in terms of percentage of T and B cells as well as myeloid cells. 
Sixteen weeks after transplantation the mean percentage of hCD34+ cells in the peripheral 
blood of mice with ohTEBCs was significantly higher than in control mice (3.1 % ± 0.3 SEM 
vs 1.9 % ± 0.3 SEM; p-value = 0.016). However, there was no significant difference in the 
other cell lineages at all other time points analyzed. After 17 weeks, at sacrifice, spleens were 
collected from all mice and the same flow cytometry analysis confirmed efficient engraftment 
and reconstitution of the human hematopoietic compartment in mice carrying the ohTEBCs 
(Fig. 5F-G).  H&E and IHC staining of spleen sections confirmed the presence of both murine 
and human hematopoietic cells as well as human CD34+ HSCs (Fig. 5H-J). At sacrifice, 
bones and BM were also harvested from the humanized orthotopic bone, the contralateral 
femurs and the femurs of control mice (CD34+ transplantation without ohTEBCs). Flow 
cytometry analysis on BM (Fig. 5K-L) and IHC staining on bone sections (Fig. 5M-N) 
confirmed the presence of huCD34+ and huCD45+ cells within ohTEBCs after transplantation.  
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Figure 5: (A) Time line for CD34+ cells transplantation to humanize the hematopoietic bone 
marrow niche in the orthotopic bone. Flow cytometry showed the presence of human 
leucocytes hCD45+ and hematopoietic hCD34+ cells as well as other immune cells at various 
time points after transplantation. Next to hCD34+ cells, human T cells (hCD3+), B cells 
(hCD19+) and hCD33+ myeloid cells could be found. (B - C) Representative images for FACS 
analysis of peripheral blood of mice at week 10 (W10). (D) Level of humanization at week 
10, 12, 14 and 16 in the peripheral blood of mice with orthotopic humanized tissue engineered 
constructs (ohTEBC = humanized bone) and without ohTEBC (Control). Human CD45+ cells 
were present at every time point. (E) Percentage of the main human hematopoietic lineages 
and human CD34+ HSCs at week 10, 12, 14 and 16 in the peripheral blood of the same mice 
as in (D). (F) Level of humanization at week 17 in the spleens of mice with ohTEBC 
(Humanized Bone) and without ohTEBC (Control). (G) Percentage of each human lineage at 
week 17 in the spleens of the same mice as in (F). (H) H&E staining of spleen tissue from 
mice with ohTEBC. (I-J), IHC staining for human specific- (hs-)CD45+ and hsCD34+ cells on 
mouse spleen tissue from mice with ohTEBC. (K) Level of humanization at week 17 in the 
bone marrow extracted from the humanized orthotopic bone (Humanized Femur), the 
contralateral femurs (Non-humanized Femur) and the femurs of control mice (Control). (L) 
Percentage of each human lineage and human CD34+ HSCs at week 17 in the BM extracted 
from the same mice as in (K). (M - N) IHC staining for human specific- (hs-)CD45+ and 
hsCD34+ cells depicted the presence of human leucocytes (M) and human hematopoietic stem 
cells (N) in ohTEBCs. Graphs depict boxplots showing bottom and top of box = 25th and 
75th percentiles, thin line inside box = median, bar = maximum and minimum of data. * p < 
0.05. 
 
OhTEBCs present a suitable bone microenvironment for OS in NSG mice 
To validate the preclinical application of the well-characterized humanized orthotopic bone 
microenvironment for the evaluation of anti-tumor therapeutics, 5x105 human luciferase-
labelled OS cells (Luc-SAOS-2) were directly injected into ohTEBCs of NOD-scid mice (n = 
10) at 6 weeks after ohTEBC implantation. After 8 weeks, we observed a tumor take rate of 
only 10% within ohTEBCs when performing in vivo and ex vivo bioluminescence imaging 
(BLI) and consecutive histological analysis (data not shown).  Lung metastasis was only 
present in one animal, other than the animal developing the orthotopic tumor (data not 
shown). When injecting the same number of Luc-SAOS-2 cells into the ohTEBCs of NSG 
mice (n = 6) 20 weeks after ohTEBCs implantation, and 15 weeks after transplantation of 
CD34+ cells, ex vivo BLI analysis 7 weeks after tumor cell injection, revealed an OS take 
rate in 100% of cases and lung metastasis in 50% of cases (Fig. 6A). Micro-CT analysis 
showed a bone-forming region within ohTEBCs that penetrated the cortex and grew outside 
the constructs (Fig. 6B). A MRI study was performed as a “proof of principle” in order to 
show, that the bone, the surrounding soft tissue and the tumor can be depicted with a typical 
clinical diagnostic tool for OS (Figure 6I).   
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Figure 6: Orthotopic humanized tissue engineered constructs (ohTEBCs) is a suitable niche 
for osteosarcoma (OS) growth. (A) Ex vivo BLI depicted a 100% tumor take rate in ohTEBCs 
(right) 7 weeks after OS cell injection. Counts > 150 were considered as a positive tumor 
signal. Contralateral control femurs (left) showed no signal. Ex vivo BLI analysis of murine 
lungs revealed lung metastasis in 50% of cases. (B) Micro-CT showed an osteoblastic tumor 
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penetrating the cortex (white arrow) and forming bone outside the ohTEBCs (black arrow). 
(C-D) Histomorphological analysis via H&E staining indicated an osteoblastic neoplasm, 
which penetrated the ohTEBC cortex (Cx) and infiltrated the surrounding musculature (Mc). 
Pathognomonic eosinophilic osteoid (Os) were abundantly distributed between the tumor 
cells, indicating that the neoplasm was indeed an OS. (E-F) Immunohistochemical staining 
showed that the infiltrating tumor cells produced human hsCol-I and were positive for Ki67, 
thus proliferating. (G) Numerous osteoclasts (red) were detected via TRAP staining where the 
cortex (Cx) was penetrated. (H) Pulmonary nodules were surrounded by lung alveoli (Av). 
Nuclei of these cell compartments were positive for hsLamin A/C and therefore proved to be 
filiae of the human orthotopic OS. (I) MRI depicted ohTEBC surrounded by muscles (Mc) 
and echogenic regions, which corresponded with the tumor infiltration site (black arrow).  
 
 Histological analysis showed that these tumors were producing human ECM proteins (hsCol-
I) and in particular human eosinophilic osteoid with features typical of the most frequent 
osteoblastic subtype of OS (Fig. 6C-E). Ki67 staining showed the proliferative nature of the 
tumour tissue (Fig. 6F). TRAP staining depicted osteoclastic activity at regions where the 
tumor penetrated the outer cortex of ohTEBCs (Fig. 6G) and infiltrated the soft tissue as well 
as peripheral nerves (Supp. Fig. 3A). H&E staining of the pulmonary lesions also showed the 
production of osteoid (Supp. Fig. 3B).  
Positive staining of the pulmonary lesions for hsLamin A/C indicated the human origin of the 
tumor cells (Fig. 6H), thus confirming that these lesions were filiae of human OS growing 
within the tissue-engineered humanized orthotopic bone. Performing magnet resonance 
imaging (MRI), ohTEBCs were found surrounded by musculature (Fig. 6I). Echogenic 
regions were near the tumor tissue, which was also detected by H&E staining and µCT.  
Humanized OS xenografts utilize human vascular components for tumor angiogenesis 
The initially implanted HUVECs were labelled with GFP via lentiviral transduction prior to 
implantation and were detected via in vivo biofluorescence imaging (IVIS Spectrum) 1 week 
post-implantation (Fig. 7A). To verify that HUVECs were still present at the time point of 
tumor harvest, we performed IHC staining for GFP and found positive immunoreactivity for 
typical vascular structures (Fig. 7B). Additionally, hsCD34 staining not only revealed the 
presence of HSCs in the BM regions of the tumor but also a network of human CD34-
expressing endothelial cells (Fig. 7C-D). To confirm the human origin of these cells, we 
stained for human-specific collagen type-IV (hsCol-IV), and found its expression in close 
proximity to endothelial cells (Fig. 7E). Additionally, multi-label fluorescence imaging for 
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GFP and hsCD34 proved that these endothelial cells are of human origin and that the tumor 
utilizes the implanted cells for tumor angiogenesis 27 weeks post-implantation (Fig. 7F-H). 
 
Figure 7: Implantation of human umbilical vein endothelial cells (HUVECs) generated a 
humanized platform for tumour angiogenesis. (A) GFP-labelled HUVECs were detected via 
in vivo fluorescence imaging (IVIS Spectrum) 1 week post-implantation of orthotopic 
humanized tissue engineered constructs (ohTEBCs). (B) Immunohistochemical staining for 
GFP, indicated the presence of HUVECs within the humanized OS model 27 weeks post-
implantation. (C-D) The tumour utilized HUVECs for neoangiogenesis as seen by positive 
staining for human specific- (hs-) CD34. The vascular network appeared with typical aspects 
of tumour angiogenesis as vessels showed an irregular network with inconsistent diameters 
and dilatations. (E) Staining for hsCol-IV additionally proved that HUVECs were active and 
produce human basal membrane compounds. Additional evidence that these cells are indeed 
the initially implanted HUVECs was provided by simultaneous fluorescence multi-labelling 
for GFP (F) and hsCD34 (G). (H) Overlay image GFP and hsCD34 with blue DAPI 
counterstaining of cell nuclei. 
 
Tumor marker expression in the humanized OS model is similar to that in OS patients 
To evaluate the expression of clinically relevant markers described by our group [10] and in 
the literature [43-48] in this humanized OS model, we performed IHC staining for ezrin (Fig. 
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8A), vascular endothelial growth factor (VEGF, Fig. 8B), hypoxia-inducible transcription 
factors 1 and 2 alpha (HIF-1α and HIF-2α) (Fig. 8C-D), and glial fibrillary acidic protein 
(GFAP, Supp. Fig. 3C). These markers were expressed in all examined tumors (n=3). We also 
confirmed the presence of these markers at the gene level by qRT-PCR analysis and found the 
corresponding genes upregulated in all tested tumors (n=2) in comparison to the untreated 
contralateral femurs (2/2) and non-tumor carrying ohTEBC controls (n=2). 
C12orf29 is expressed in the humanized OS model and in OS patients 
Our group recently discovered the expression of C12orf29 in sheep bones and human fetal 
vertebras, and reported evidence for its role in skeletal maturation [16]. Thus, we sought to 
evaluate its expression in patient samples and the humanized OS model. We found  positive 
C12orf29 staining in the tumors, which was mainly extracellular as previously described [16], 
and a significantly upregulated gene expression in the tumors compared to the contralateral 
healthy femurs and non-tumor bearing ohTEBCs (Fig. 8E). 
In order to translate this new finding into a clinical setting, we analyzed tissue microarrays 
(TMAs) of OS patients (n = 68) without chemotherapy prior to tissue dissection via IHC (see 
Table 1 for patients’ characteristics). C12orf29 was expressed in a large number of patient 
tissues, although we did not find a co-expression with Col-II as expected due to previous 
reports (Fig. 9A-C) [16]. Using cell count analysis, we found a mean percentage of 24.1 ± 
3.2% of C12orf29-positive cells when including all pre-chemotherapy patients. Linear 
regression analysis showed no significant correlation of C12orf29 expression and 
proliferation of the tumors when comparing cell counts of Ki67 staining (R2 = 0.186). There 
were no significant differences in tumor stage according to the Union for International Cancer 
Control (UICC) and histological grading (Supp. Table 3).  
Linear regression analysis of OS after chemotherapy revealed a weak but non-significant 
correlation between the percentage of C12orf29-positive cells and the Salzer-Kuntschick 
score, a histological measure for tumor response to chemotherapy (R2 = 0.598). Nevertheless, 
we found a high percentage of C12orf29-positive cells in the tissues of patients with 
osteoblastic, mixed osteoblastic/chondroblastic and chondroblastic OS subtype (Fig. 9D; 
Supp. Table 3). There was a significantly higher C12orf29 expression in mixed osteo-
/chondroblastic tumors than in chondroblastic OS. We found no correlation between 
C12orf29 and Ki67 expression performing separate linear regression analysis for these groups 
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Figure 8: Tumor marker expression in humanized tissue engineered constructs (ohTEBCs). Ezrin, vascular 
endothelial growth factor (VEGF), hypoxia-inducible factor 1-alpha (HIF-1α), hypoxia-inducible factor 2-
alpha (HIF-2α) and C12orf29 were expressed in tumor tissues as indicated by immunohistochemical 
staining (A-E, left column). RT-PCR analysis showed an upregulation in osteosarcoma (OS) homed in the 
ohTEBCs (ohTEBC+OS) in comparison to ohTEBCs without tumours and the contralateral control femurs 
(A-E, right column). Gene levels are depicted as mean relative fold expression (2-∆∆CT) ± SEM. * indicates 
significant differences between groups with p < 0.05, ** p < 0.01, *** p ≤ 0.001.  
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Figure 9: C12orf29 expression in osteosarcoma (OS) patients. A-C) Immunohistochemical 
staining of 3 different OS patients. (A) OS with evident C12orf29 expression (left) in areas 
where Col-II (middle) and hyaline cartilage (right, purple areas) were found. B) OS with no 
Col-II staining although C12orf29 was present. C) OS with Col-II expression in regions 
where no C12orf29 was detected. D) Comparing the mean percentage of C12orf29-positive 
cells, the highest expression was found in mixed osteo-/chondroblastic OS, which was 
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significantly different to osteoblastic OS (* p < 0.001) but not to chondroblastic OS (See 
Table 1 for detail). There was no difference in Ki67 expression when comparing all subtypes. 
E) OS primarily located at the jaw or temporal region showed a significantly higher C12orf29 
expression compared to OS originating from an extremity (* p = 0.008). C12orf29 expression 
in OS located at the trunk was lower than in OS at the jaw or temporal region, without 
reaching statistical significance. There was no difference in Ki67 expression when comparing 
all patient groups. F) There was no difference in the mean percentages of C12orf29- or Ki67-
positive cells when comparing patients without and after chemotherapy. Graphs depict 
boxplots showing bottom and top of box = 25th and 75th percentiles, grey thick line inside 
box = mean, thin line inside box = median, bar = maximum and minimum of data, black dots 
= outliers. * indicates significant differences between groups. 
 
 
(Table 2); but a significant difference was observed when comparing the tumor site (Fig. 9E; 
Supp. Table 3). C12orf29 expression was lower in OS located at the trunk than in OS situated 
at the jaw or temporal region, without reaching significance (p = 0.576). However, the latter 
patient group showed a significantly higher mean percentage of C12orf29-positive cells than 
patients with the primary tumour at an extremity (p = 0.008). There was a strong correlation 
between C12orf29 and Ki67 expression when performing regression analysis for patients with 
OS originating from the trunk (R2 = 0.849) or the jaw/temporal region (R2 = 0.710; Table 2). 
There was no difference in the mean percentages of C12orf29- or Ki67-positive cells when 
comparing patients without and after chemotherapy (Fig. 9F). Altogether these data indicate 
the function of C12orf29 in OS and suggest further preclinical investigations on C12orf29 and 
OS.  
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Linear Regression Analysis 
C120rf29 and Ki67 
 n = Pearson 
correlation 
R 
R2 
All Patients prior chemotherapy 7 0.432 0.186 
After Chemotherapy 7 0.134 0.018 
Osteoblastic 40 0.328 0.108 
Mixed osteo-/chondroblastic 11 0.619 0.383 
Chondroblastic 8 0.699 0.489 
Extremity 52 0.425 0.181 
Trunk 7 0.921 0.849 
Jaw/temporal 5 0.843 0.710 
    
Table 2: Results of linear regression analysis expressed as R and R2. 
 
 
Discussion 
Human tumor xenografts that interact with a murine-only tissue microenvironment behave 
considerably different than in a human microenvironment [49-54]. Tumor cells recruit a 
variety of different cell types, including immune cells, fibroblasts and endothelial cells, to 
build the niche for a developing tumor [55]. In order to minimize false interspecies-crosstalk 
Shtivelman et al. were the first to describe a tissue-engineered top-down approach by 
implanting human fetal lung and BM pieces to develop an “all-human model” for studies on 
metastasis of lung cancer to human bone [50]. After intravenous injection of human lung 
cancer cells, the majority of cells homed to the implanted human tissues. Xia et al. applied 
this approach to breast cancer by incorporating both subcutaneous human breast and bone 
implants [56, 57]. Human breast cancer cells exhibited a significantly higher tumorigenicity 
upon injection into human tissues compared to murine counterparts, suggesting that species-
specific microenvironmental factors promote human cancer cell growth [56].  
Orthotopic engraftment sites comprise more physiological features compared to ectopic 
growth sites as not only cellular but also ECM components influence tumor biology [5, 
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7, 10, 17, 58-60]. Important differences between ectopic and orthotopic bone 
microenvironments have been reported from a biochemical and biomechanical point of view 
[61]. Orthotopic bone implants are exposed to higher loads and strains than ectopic implants 
and have therefore higher bone remodeling rates and bone mineral density as well as bone 
volume fraction [62, 63]. Migration and proliferation of tumor cells also can be influenced by 
mechanical signals [64, 65]. Consequently, an orthotopic bone model is favorable for bone 
tumor research. To date, no orthotopic humanized bone microenvironment has been reported. 
Therefore, tissue-engineered a humanized organ bone by including a comprehensive suite of 
human bone and BM cellular and extracellular components at an orthotopic growth site. We 
demonstrated that this tissue engineering approach offers the possibility to independently 
change experimental parameters on a cellular and molecular level, depending on the research 
question. The addition of hBM-MSCs enhanced tissue properties and promoted a higher 
degree of humanization of the mineralized tissue and a higher amount of blood-containing 
BM. We selected hBM-MSCs as Reinisch et al. showed that the addition of MSCs improves 
BM cell homing dependent on the type of MSCs [39]. It was reported that hBM-MSCs have a 
greater potential to support engraftment of transplanted human CD34+ cells compared to 
MSCs isolated from white adipose tissue or umbilical cord [66]. Various techniques have 
been described to engraft a humanized hematopoietic and immune system to investigate 
hematologic and metastatic bone malignancies [13, 42, 67-69]. This is particularly important 
as circulating cancer cells compete with HSCs when homing to the BM microenvironment 
and alter their metastatic spread in the presence of human HSCs [70]. We describe a human 
hematopoietic system at a humanized orthotopic growth site and demonstrate that 
transplanted human CD34+ cells not only colonize the ohTEBCs but also that the 
presence of ohTEBCs does not affect their ability to colonize the whole mouse organism 
and differentiate into all cell linages of a reconstituted hematopoietic and immune 
system. A next step is to investigate the intercellular communication between 
transplanted cells and the different homing sites in order to dissect differences on a 
molecular level and in cell function. 
As the perivascular BM niche is important for the homing of transplanted HSCs Chen et al.  
utilized hBM-MSCs and added endothelial colony-forming cells to recreate a vascular 
network within a bone construct [12]. Similar to our findings, human vascular components 
were discovered at the endpoint of their study. However, we are the first to show 
engraftment of human endothelial cells in vivo at an orthotopic growth site. Additionally, 
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while Chen and colleagues investigated a BM malignancy - namely multiple myeloma - we 
examined the properties of a solid primary bone tumor. The critical vehicle for HUVEC 
integration were starPEG heparin gels. Fernandez-Perez et al. were the first to describe these 
hydrogels as a platform to generate a capillary network in collaboration with our group [71]. 
StarPEG heparin gels were characterized by Freudenberg et al. in detail in 2009 and were 
previously applied as an in vivo vehicle for HUVECs by our group in order to generate a 
humanized periosteum construct [19, 34]. Herein, we further show for the first time that 
an established solid primary bone tumor exploits the co-transplanted GFP-labelled 
HUVECs for tumor neo-angiogenesis and that these cells remain viable for over 27 
weeks in vivo. The simultaneous expression of GFP, hsCD34 and hsCol-IV, the latter being a 
basement membrane protein, proved that these cells were of human origin and indeed were 
the previously implanted endothelial cells. These findings confirm our hypothesis that one can 
engineer a humanized bone organ, combining human bone matrix, a humanized 
hematopoietic system, a human solid bone tumor and a humanized vascular niche. The high 
level of in vivo integration of these human tissue elements was not only facilitated by 
utilizing a combination of modern tissue engineering vehicles like PCL scaffolds and 
hydrogels but also by the use of immunocompromised mice like NOD-scid and even 
more NSG mice [72]. Due their immunodeficiency, the animals on their own can not 
mimic human OS completely. Therefore, the approach of humanization – including 
transplantation of human HSCs and introducing a humanized immune system  – tries to 
narrow the gap between mice and men [3, 8, 21, 40, 73]. 
 
Of clinical relevance, we engineered a humanized OS model that has the histomorphological 
and clinical patterns of the most common osteoblastic OS subtypes [74]. The tumors were 
producing tumor osteoid pathognomonic for OS and utilized osteoclasts to resorb the bone 
cortex and to infiltrate the surrounding muscle and soft tissues. Our preclinical model also 
generated lung metastasis, which is the most typical clinical pathology for OS patients [43, 
44]. Importantly, we found an upregulation of previously described OS markers [10, 43, 45-
48]. The angiogenic markers VEGF, HIF-1α and HIF-2α were overexpressed in the 
humanized OS model compared to normal murine bone and orthotopic humanized bone. 
Overexpression of VEGF has been correlated with poor survival of OS patients previously 
[43, 45]. We reported that HIF-2α was upregulated in OS in a previous study utilizing 
subcutaneous ectopic pelvic bone chips transplanted together with rhBMP-7 into NOD-scid 
mice [10]. Whereas HIF-1α induces neovascularization in early hypoxic events, HIF-2α plays 
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a role in chronic hypoxia and tumor growth. However, the exact contribution of both factors 
in tumor progression remains unknown to date [75, 76]. GFAP and ezrin are expressed in OS, 
and the upregulation of ezrin is linked to increased metastasis and poor prognosis in OS 
patients [47, 48]. 
A previous study from our group led us to evaluate the expression of C12orf29 [16]. This 
gene is believed to promote the development of the musculoskeletal system; however, its 
cellular functions remain unknown. We found a high expression of C12orf29 in the 
humanized OS model compared to control femurs and ohTEBCs. The analysis of TMAs from 
OS patients revealed a frequent upregulation of C12orf29, especially in the most common 
subtypes of OS. In particular, the chondroblastic subtype seems to be linked to the presence of 
C12orf29, which is consistent with the finding that this gene is found to be expressed in Col-
II-rich regions [16]. However, in our patient cohort, we did not detect a consistent co-
expression of C12orf29 with Col-II. To test whether C12orf29 is linked to highly aggressive 
OS, we performed regression analysis with Ki67 expression, a marker for tumor proliferation. 
Although we did not find a significant correlation of C12orf29 with the overall tumor 
proliferation, independent of the OS subtype, we detected a significantly higher expression of 
C12orf29 in tumors in the jaw/temporal region compared to OS originating from the 
extremities (peripheral OS). Furthermore, we found a significant correlation between 
C12orf29 and Ki67 expression for OS originating from the trunk (axial OS) or the 
jaw/temporal region. This suggests that a high C12orf29 expression of OS located in this 
region is linked to more aggressive tumors, which is in line with the literature suggesting a 
poor prognosis for axial OS [2]. Although our patient cohort was heterogeneous, due to 
limited availability of clinical data, our findings justify the efforts to initiate future preclinical 
research to decipher the function of C12orf29 in OS. 
Conclusion 
To our knowledge we are the first to develop, characterize and validate an orthotopic bone 
tumor research platform that provides a humanized bone matrix and a BM, whose tissue 
microenvironment can be tailored at various stages. This platform meets all requirements 
defined by the American Association for Cancer Research, in which patient specific BM cells, 
stromal and tumor cells are combined into one humanized in vivo platform to test patient-
specific drug regimens prior to the administration to patients [55]. 
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